TG Therapeutics financials
$56.190.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $616.3M | $329.0M | $233.7M | $2.8M | $6.7M | $152.0K | $152.0K | $152.0K | $152.0K | $152.0K |
| Gross profit | $515.6M | $290.5M | $219.5M | $2.5M | $5.9M | $152.0K | $152.0K | $152.0K | $152.0K | $152.0K |
| Gross margin | 83.7% | 88.3% | 94.0% | 90.5% | 88.2% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $123.3M | $41.9M | $20.6M | -$218.3M | -$344.8M | -$273.6M | -$167.6M | -$172.6M | -$117.6M | -$78.6M |
| Net income | $447.2M | $23.4M | $12.7M | -$223.8M | -$348.1M | -$279.4M | -$172.9M | -$173.5M | -$118.5M | -$78.3M |
| Net margin | 72.6% | 7.1% | 5.4% | −8036.3% | −5204.1% | −183803.3% | −113730.9% | −114132.9% | −77944.7% | −51482.2% |
| Diluted EPS | $2.77 | $0.15 | $0.09 | $-1.65 | $-2.63 | $-2.42 | $-1.96 | $-2.30 | $-1.91 | $-1.60 |
| EBITDA | $123.4M | $42.0M | $20.8M | -$218.0M | -$342.4M | -$273.2M | -$167.6M | -$172.5M | -$117.4M | -$78.1M |
| Operating cash flow | -$24.8M | -$40.5M | -$31.4M | -$176.2M | -$295.6M | -$214.5M | -$132.8M | -$128.9M | -$93.8M | -$61.6M |
| Free cash flow | -$25.0M | -$40.6M | -$31.4M | -$176.2M | -$296.0M | -$214.9M | -$132.9M | -$129.0M | -$93.8M | -$61.9M |
| Diluted shares | 161.4M | 160.3M | 148.5M | 135.4M | 132.2M | 115.3M | 88.4M | 75.5M | 62.1M | 49.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $79.1M | $179.9M | $92.9M | $102.3M | $298.9M | $553.4M |
| Short-term investments | $62.8M | $131.1M | $124.6M | $59.4M | $15.9M | $52.0M |
| Total debt | $245.6M | $244.4M | $100.1M | $71.1M | $67.8M | $29.9M |
| Total assets | $1.06B | $577.7M | $329.6M | $193.6M | $379.6M | $625.6M |
| Total liabilities | $415.2M | $355.3M | $169.1M | $135.0M | $142.5M | $106.3M |
| Shareholders' equity | $648.0M | $222.4M | $160.5M | $58.6M | $237.2M | $519.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology